ライフサイエンスコーパス: long-acting

1 ould facilitate the rational design of novel long-acting A2A agonists with improved clinical efficacy

2 ort-acting GLP-1 agonists may be superior to long-acting agonists when aiming specifically to reduce

3 in response to systemic administration of a long-acting analog of the gut-hormone glucagon-like pept

4 nisms mediating the actions of GLP-1 and its long-acting analogs on adipose tissue as well as the bra

5 paracasei NFBC 338 transformed to express a long-acting analogue of GLP-1 or the isogenic control mi

6 A long-acting analogue of PYY3-36 would therefore have gre

7 We further showed that treatment of a long-acting anandamide in wild-type mice at midgestation

8 siRNA-GalNAc conjugates are hepatotropic and long-acting and have the potential to treat a wide range

9 e malaria prophylactic drug due to its being long-acting and having a high potency against blood stag

10 th intensified treatment of midgut NETs with long-acting and repeatable octreotide, PRRT reduced the

11 lead optimization to deliver highly potent, long-acting, and efficacious preclinical inhaled PDE4 in

12 ocal inactivation of KOR by injection of the long-acting antagonist nor-BNI in the ventral tegmental

13 Long-acting anti-HIV products can substantively change t

14 We further show that prototype long-acting anti-VEGF drugs (LAVAs) that include this pe

15 91) and those who were not receiving inhaled long-acting anticholinergic medication (difference in co

16 those with asthma and those not receiving a long-acting anticholinergic medication, newly prescribed

17 bination with an inhaled corticosteroid or a long-acting antimuscarinic agent.

18 apy, providing a window for prophylaxis with long-acting antiresorptives.

19 gonists as a new class of immune-stimulating long-acting antiretroviral agents.

20 ly less on longer term developments, such as long-acting antiretroviral drugs and bNAbs, unless the c

21 phasis on oral PrEP, intravaginal rings, and long-acting antiretroviral drugs would increase.

22 NP; PC7A), in human PBMCs induces potent and long-acting antiretroviral response against several labo

23 Long-acting antiretroviral therapy (LA-ART) is currently

24 here is reason for optimism that advances in long-acting antiretroviral therapy and HIV prevention st

25 In the phase 2b Long-Acting antireTroviral Treatment Enabling (LATTE) tr

26 es, and are being considered as partners for long-acting antiretrovirals for use in therapy or preven

27 The need for long-acting ART is significant and highlighted by limita

28 rier encasement must be boosted to establish long-acting ARV depots.

29 ndividuals receiving benzodiazepine involved long-acting benzodiazepine use.

30 days) benzodiazepine use, prescription of a long-acting benzodiazepine, and benzodiazepine prescript

31 epine days' supply, first prescription for a long-acting benzodiazepine, and recent prescription opio

32 Chronic stimulation of the beta2AR by long acting beta-agonists used in the treatment of asthm

33 corticosteroid, fluticasone furoate, and the long-acting beta agonist, vilanterol could improve survi

34 costeroid (ICS) fluticasone furoate (FF) and long-acting beta(2) -agonist (LABA) vilanterol (VI) on e

35 eceptor antagonist (LTRA step-up therapy) or long-acting beta(2)-agonist (LABA step-up therapy).

36 ids (ICSs) are insufficient include adding a long-acting beta(2)-agonist (LABA) or increasing the ICS

37 to high-dosage inhaled corticosteroids plus long-acting beta(2)-agonists (ICS plus LABA) and a histo

38 c despite taking inhaled corticosteroids and long-acting beta(2)-agonists.

39 iple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS/LABA).

40 A allele of rs1042713 (Arg16 amino acid) and long-acting beta-agonist (LABA) exposure for asthma exac

41 Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocor

42 ropionate dose [<600 vs >/=600 mug/day], and long-acting beta-agonist [LABA] use [yes/no]).

43 ination ICS/short-acting beta-agonist or ICS/long-acting beta-agonist inhaler as a reliever rather th

44 of fluticasone or greater with or without a long-acting beta-agonist versus 100 mug or less assigned

45 ed corticosteroids (ICSs), with or without a long-acting beta-agonist, achieved the MID.

46 a medium-dose inhaled corticosteroid plus a long-acting beta-agonist.

47 h mild to moderate COPD included 2 trials of long-acting beta-agonists (LABAs) (n = 3174), 1 RCT of L

48 The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of a

49 The efficacy and safety of long-acting beta-agonists (LABAs) have been questioned.

50 Long-acting beta-agonists (LABAs) have been shown to inc

51 led glucocorticosteroid therapy with/without long-acting beta-agonists (LABAs).

52 se to high-dose inhaled glucocorticoids plus long-acting beta-agonists (LABAs).

53 Among patients treated with long-acting beta-agonists and medium-to-high doses of in

54 remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of in

55 corticosteroids alone or in combination with long-acting beta-agonists might result in improved long-

56 Effects of small-particle long-acting beta-agonists on the small airways have been

57 Long-acting beta-agonists were not allowed during the tr

58 an be refractory to inhaled corticosteroids, long-acting beta-agonists, and leukotriene receptor anta

59 dosing effects of small- and large-particle long-acting beta-agonists.

60 uncontrolled by inhaled corticosteroids and long-acting beta-agonists.

61 gh-dose inhaled corticosteroids and frequent long-acting beta-agonists.

62 the mechanisms by which corticosteroids and long-acting beta2 -adrenergic agonists confer protection

63 rticosteroids alone or in combination with a long-acting beta2 -adrenergic receptor agonist (LABA) on

64 avioral analyses revealed that formoterol, a long-acting beta2 adrenergic receptor agonist, caused si

65 corticosteroids (ICS) or low-dosage ICS plus long-acting beta2 agonist fixed-combination therapy at s

66 -to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist require additional treatment o

67 -to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist were eligible for participatio

68 -to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist, irrespective of baseline eosi

69 OPD and treated with inhaled corticosteroid, long-acting beta2 agonist, long-acting muscarinic antago

70 Combination inhaled therapy with long-acting beta2 agonists (LABAs) and corticosteroids i

71 nary disease (COPD) and, in combination with long-acting beta2 agonists, reduce exacerbations and imp

72 ed to high-dose inhaled corticosteroids plus long-acting beta2 agonists.

73 t formoterol, a potent, highly specific, and long-acting beta2-adrenergic agonist, induces renal mito

74 , and others have shown that combinations of long-acting beta2-adrenergic agonists (LABAs) and long-a

75 Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist

76 Salmeterol is a long-acting beta2-adrenergic receptor agonist used to tr

77 vere disease who will inevitably be taking a long-acting beta2-adrenoceptor agonist (LABA)/ICS combin

78 mic effects can be significantly enhanced by long-acting beta2-adrenoceptor agonists (LABAs) and may

79 g muscarinic receptor antagonists (LAMA) and long-acting beta2-adrenoreceptor agonists (LABA), are th

80 S) and inhaled corticosteroids combined with long-acting beta2-agonist (ICS/LABA) are standard treatm

81 ycopyrrolate), a fixed-dose combination of a long-acting beta2-agonist (indacaterol) and a long-actin

82 erapy with dual inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) therapy in patients wit

83 nts with COPD from an inhaled corticosteroid/long-acting beta2-agonist combination treatment to tripl

84 responsiveness to an inhaled corticosteroid/long-acting beta2-agonist combination versus a long-acti

85 Inhaled corticosteroids and long-acting beta2-agonist combinations are more effectiv

86 o 7 (maximum 14) days inhaled corticosteroid/long-acting beta2-agonist fluticasone furoate/vilanterol

87 in addition to inhaled corticosteroids plus long-acting beta2-agonist therapy could improve the live

88 erapy with fixed-dose inhaled corticosteroid/long-acting beta2-agonist therapy was analyzed.

89 r without a leukotriene receptor antagonist; long-acting beta2-agonist therapy was not permitted duri

90 s year, and receiving inhaled corticosteroid/long-acting beta2-agonist with or without LAMA daily for

91 aler therapy with an inhaled corticosteroid, long-acting beta2-agonist, and long-acting muscarinic an

92 Salmeterol is a long-acting beta2-agonist, widely used as an inhaled tre

93 l/glycopyrronium 110/50 mug with twice-daily long-acting beta2-agonist/inhaled corticosteroid salmete

94 cerbations) study, which compared once-daily long-acting beta2-agonist/long-acting muscarinic antagon

95 ng-acting beta2-agonist combination versus a long-acting beta2-agonist/long-acting muscarinic antagon

96 e on high-dosage inhaled corticosteroids and long-acting beta2-agonists (ICS plus LABA) in the previo

97 Long-acting beta2-agonists (LABA) and leukotriene recept

98 Long-acting beta2-agonists (LABA) were shown to inhibit

99 Safety concerns associated with long-acting beta2-agonists (LABAs) have led to many US F

100 The use of inhaled long-acting beta2-agonists alone is not appropriate.

101 d on inhaled corticosteroids with or without long-acting beta2-agonists and in patients with COPD wit

102 dysplasia and exposure to the combination of long-acting beta2-agonists and inhaled corticosteroids (

103 for renal dysplasia associated with combined long-acting beta2-agonists and inhaled corticosteroids.

104 Use of long-acting beta2-agonists before achieving a reduction

105 hort-acting beta2-agonist albuterol, and the long-acting beta2-agonists formoterol and olodaterol.

106 tment (high-dose inhaled corticosteroids and long-acting beta2-agonists or medium- to high-dose inhal

107 The LOB that occurs with chronic long-acting beta2-agonists use is not affected by ADRB2

108 roids combined with oral corticosteroids and long-acting beta2-agonists) were extracted from 65 Dutch

109 erapy, including inhaled corticosteroids and long-acting beta2-agonists, is effective in patients for

110 lator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment

111 Combination long-acting bronchodilator treatment might be more effec

112 or the efficacy of "triple therapy" with two long-acting bronchodilators and an inhaled corticosteroi

113 for the efficacy of triple therapy with two long-acting bronchodilators and an inhaled corticosteroi

114 Other controller medications, such as long-acting bronchodilators and biologics, may be requir

115 New long-acting bronchodilators and their combinations are c

116 Several studies have documented that long-acting bronchodilators can reduce exacerbation rate

117 f inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.

118 inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients w

119 ) strategy recommends the combination of two long-acting bronchodilators of different pharmacologic c

120 enefit of LABA/LAMA combinations over single long-acting bronchodilators or LABA/inhaled corticostero

121 ith little inflammation and might respond to long-acting bronchodilators, including long-acting musca

122 efore pregnancy, especially prescriptions of long-acting bronchodilators.

123 hose disease is not adequately controlled by long-acting bronchodilators.

124 rt to understand the factors associated with long-acting cabotegravir (GSK1265744 LAP) pharmacokineti

125 gravir plus rilpivirine at 4-week intervals (long-acting cabotegravir 400 mg plus rilpivirine 600 mg;

126 g; two 2 mL injections) or 8-week intervals (long-acting cabotegravir 600 mg plus rilpivirine 900 mg;

127 ssessment, three intramuscular injections of long-acting cabotegravir 800 mg or saline placebo at 12

128 rse events was higher in participants in the long-acting cabotegravir group (n=75 [80%]) than in thos

129 afety, tolerability, and pharmacokinetics of long-acting cabotegravir injections in healthy men not a

130 e randomly assigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week inte

131 The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks

132 The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenanc

133 , mild-to-moderate injection-site reactions, long-acting cabotegravir was well tolerated with an acce

134 months of becoming pregnant and only 1 had a long-acting contraceptive prescribed.

135 drug conjugates are promising candidates for long-acting drug delivery systems to treat chronic disea

136 The success of long-acting drugs like tiotropium support this hypothesi

137 e that once-daily dosing with dasotraline, a long-acting, dual monoamine reuptake inhibitor, may be a

138 Live mice received HS containing a long acting epithelial sodium channel blocker (P308); is

139 While first generation long acting/extended release (LA/ER) DD Systems (DDS) cu

140 It is feasible to place a long-acting FAi in an outpatient setting, without prolon

141 We used native-FGF21 and a long-acting FGF21 (PF-05231023), to determine the contri

142 tidic C3 inhibitor, compstatin Cp40, and its long-acting form (polyethylene glycol [PEG]-Cp40) on hem

143 in response to short-acting (salbutamol) and long-acting (formoterol) beta2 -agonists.

144 The injectable long-acting formulation of rilpivirine (TMC278LA) is a p

145 a general and effective strategy to generate long-acting functional antibodies, and may lead to a sel

146 ntagonist to its binding protein generates a long acting GHR antagonist and we confirmed that introdu

147 odel of diet-induced obesity (DIO) using the long-acting GIP analog [d-Ala(2)]GIP.

148 ears or older, all of whom were treated with long-acting (glargine, detemir) or neutral protamine Hag

149 We assessed the safety and efficacy of the long-acting GLP-1 analogue, liraglutide, in patients wit

150 The clinical efficacies of long-acting GLP-1 derivatives strongly support discovery

151 Liraglutide, a long-acting GLP-1 receptor agonist, is approved for trea

152 s of GLP-1R agonists, the data indicate that long-acting GLP-1R agonists influence body weight by reg

153 f Glp1r and then administered liraglutide, a long-acting GLP1R agonist.

154 glucose- and body weight-lowering effects of long-acting GLP1R agonists are via direct action on CNS

155 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-1) analogue tha

156 aimed to compare the efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dul

157 Long-acting IL-4 complex (IL-4c; recombinant IL-4 mixed

158 term management, including inhaled steroids, long-acting inhaled beta2-stimulants, and leukotriene re

159 A potent and long acting inhibitor of pKal activity could be an effec

160 zapine (HR, 0.58; 95% CI, 0.53-0.63) and all long-acting injectable antipsychotic medications (HRs 0.

161 Long-acting injectable antipsychotic medications were as

162 Clozapine and long-acting injectable antipsychotic medications were th

163 risk of relapse and likely to benefit from a long-acting injectable antipsychotic.

164 Long-acting injectable antipsychotics are used to reduce

165 Long-acting injectable antiretroviral (LA-ARV) drugs wit

166 Long-acting injectable antiretroviral agents are being d

167 he medium term (offering intravaginal rings, long-acting injectable antiretroviral drugs) and long te

168 Long-acting injectable antiretrovirals such as rilpiviri

169 ur findings support further investigation of long-acting injectable cabotegravir as an alternative to

170 e are antiretroviral drugs in development as long-acting injectable formulations.

171 phenazine (HR, 0.58; 95% CI, 0.52-0.65), and long-acting injectable olanzapine (HR, 0.58; 95% CI, 0.4

172 lowest during monotherapy with once-monthly long-acting injectable paliperidone (hazard ratio [HR],

173 7), clozapine (HR, 0.53; 95% CI, 0.48-0.58), long-acting injectable perphenazine (HR, 0.58; 95% CI, 0

174 his could be overcome by the introduction of long-acting injectable PrEP agents, which may be adminis

175 Long-acting injectable PrEP, which is in development, ma

176 The first long-acting injectable product (Depo-Provera(R)) was app

177 The use of long-acting injectable risperidone after a first episode

178 Long-acting injectable risperidone better controlled mea

179 ients randomized, 3 refused treatment in the long-acting injectable risperidone group.

180 of schizophrenia were randomized to receive long-acting injectable risperidone or oral risperidone.

181 italization is about 20% to 30% lower during long-acting injectable treatments compared with equivale

182 The relative effectiveness of long-acting injectable versions of second-generation and

183 A 12-month trial comparing the long-acting injectable vs oral risperidone and cognitive

184 hazard ratio [HR], 0.51; 95% CI, 0.41-0.64), long-acting injectable zuclopenthixol (HR, 0.53; 95% CI,

185 to the more consistent administration of the long-acting injectable.

186 Long-acting, injectable, second-generation antipsychotic

187 Purpose The association between long-acting insulin analogs and increased breast cancer

188 95% CIs of incident breast cancer, comparing long-acting insulin analogs with NPH overall, as well as

189 se challenge improved over a clinically used long-acting insulin derivative.

190 r (DET) reduces glycemia comparably to other long-acting insulin formulations but causes less weight

191 In direct comparison with another long-acting insulin, insulin glargine (GLAR), DET led to

192 scriptions and percentage of patients taking long-acting insulins who filled analogue prescriptions.

193 results of the first phase 3 trial assessing long-acting intramuscular pasireotide in patients with C

194 nted by a single high dose (30 mg/kg) of the long-acting KOR antagonist norbinaltorphimine (nor-BNI),

195 sfer inhibitor that has been formulated as a long-acting (LA) injectable suitable for monthly to quar

196 After mesh placement, a long-acting local anesthetic (bupivacaine hydrochloride,

197 Administration of a long-acting local anesthetic between the mesh and the pe

198 However, long-acting medications are rarely used following a firs

199 Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as tr

200 ong-acting beta2-agonist (indacaterol) and a long-acting muscarinic antagonist (glycopyrrolate), comp

201 t (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-ch

202 mbination versus a long-acting beta2-agonist/long-acting muscarinic antagonist combination for exacer

203 ompared once-daily long-acting beta2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrro

204 ticosteroids (ICS) (n = 1097), 5 RCTs of the long-acting muscarinic antagonist tiotropium (n = 4592),

205 d corticosteroid, long-acting beta2 agonist, long-acting muscarinic antagonist, and leukotriene recep

206 rticosteroid, long-acting beta2-agonist, and long-acting muscarinic antagonist, several of which are

207 Other controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and

208 acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide great

209 nd to long-acting bronchodilators, including long-acting muscarinic antagonists, to reduce hyperinfla

210 Recent studies have suggested that the long-acting muscarinic receptor antagonist tiotropium, a

211 Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and l

212 Long-acting nanoART can serve as a drug carrier in both

213 Moreover, a long-acting nanoformulation of compound I [compound I na

214 Long-acting nanoformulations of RIF and an INH derivativ

215 only prescribed calcium channel blockers and long-acting nitrates at discharge (DM versus not: 27.9%

216 development of novel medical treatments (eg, long-acting octreotide formulations, mTOR inhibitors, an

217 Long-acting octreotide treatment diminished (68)Ga-DOTAT

218 Although the long-acting opiate methadone is commonly used to treat d

219 The long-acting opioid group was followed up for a mean 176

220 Maintaining addicted pregnant women on long-acting opioid receptor agonist is the most common s

221 e in incidence of death) were calculated for long-acting opioid therapy vs control medication.

222 e HR during the first 30 days of therapy (53 long-acting opioid, 13 control deaths) was 4.16 (95% CI,

223 The HR for cardiovascular deaths (79 long-acting opioid, 36 control deaths) was 1.65 (95% CI,

224 eaths other than unintentional overdose (120 long-acting opioid, 53 control deaths), the HR was 1.72

225 risk was due to out-of-hospital deaths (154 long-acting opioid, 60 control deaths; HR, 1.90; 95% CI,

226 new episodes of prescribed therapy for both long-acting opioids and control medications (mean [SD] a

227 Long-acting opioids are a leading cause of accidental de

228 Prescription of long-acting opioids for chronic noncancer pain, compared

229 Long-acting opioids increase the risk of unintentional o

230 tched new episodes of prescribed therapy for long-acting opioids or either analgesic anticonvulsants

231 Long-Acting Parenterals (LAPs) have been used in the cli

232 ACTs combine ART or its derivative with a long-acting partner drug to maximize efficacy during the

233 y assigned (1:1:1) to receive treatment with long-acting pasireotide (60 mg intramuscularly every 28

234 e aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alo

235 41 patients (39.0%, 95% CI 24.2-55.5) in the long-acting pasireotide group, 14 of 42 patients (33.3%,

236 in nine countries: 41 were allocated to the long-acting pasireotide group, 42 to the everolimus grou

237 eatment exposure date: two (5%) of 41 in the long-acting pasireotide group, six (14%) of 42 in the ev

238 Long-acting pasireotide is an efficacious treatment opti

239 rse events with a suspected association with long-acting pasireotide monotherapy were diarrhoea (15 [

240 rse events with a suspected association with long-acting pasireotide monotherapy were gamma-glutamylt

241 INTERPRETATION: Long-acting pasireotide normalised mUFC concentration in

242 No deaths were suspected to be related to long-acting pasireotide treatment.

243 hypothesis, the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in

244 and 2) reduction of HA in the muscle ECM by long-acting pegylated human recombinant PH20 hyaluronida

245 ow that systemically administering a potent, long-acting PEGylated TRAIL (TRAILPEG) is profoundly ant

246 d an alternative technology for generating a long acting potent GHR antagonist through translational

247 ness, 62%; cost per patient, $150/year), and long-acting PrEP (effectiveness, 75%; cost per patient,

248 Over 5 years, long-acting PrEP cost $1.6 billion when provided to 50%

249 Compared with no PrEP, standard PrEP and long-acting PrEP cost $580 and $870 more per woman, resp

250 Compared with standard PrEP, long-acting PrEP was very cost-effective ($150/life-year

251 on a lifetime basis, both standard PrEP and long-acting PrEP were cost saving, compared with no PrEP

252 Long-acting PrEP will likely be a very cost-effective im

253 of resistant virus by persistent exposure to long-acting PrEP.

254 l endometrial vasculature in women receiving long-acting progestin-only contraceptives (LAPCs) are un

255 onstrates its promise for the development of long-acting protein therapeutics with high potency and s

256 eneral and versatile strategy for generating long-acting protein therapeutics.

257 he recipient's immune-reactivity by means of long-acting recombinant adeno-associated viral vectors (

258 e proportion with viral suppression for each long-acting regimen is not worse than the oral regimen p

259 At 32 weeks following randomisation, both long-acting regimens met primary criteria for comparabil

260 ong-acting somatostatin analogues octreotide long-acting release and lanreotide for advanced SI-NET.

261 ses of the somatostatin analogue pasireotide long-acting release compared with active control (octreo

262 ) trial evaluated the efficacy and safety of long-acting release octreotide (octreotide LAR) for the

263 response system to receive 40 mg pasireotide long-acting release once every 28 days for 24 weeks, 60

264 very 28 days for 24 weeks, 60 mg pasireotide long-acting release once every 28 days for 24 weeks, or

265 materials used in US FDA-approved parenteral long-acting-release (LAR) products.

266 us best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularl

267 E PET/CT scanning before and after receiving long-acting repeatable octreotide (Sandostatin LAR) were

268 mal limit) and had received 30 mg octreotide long-acting repeatable or 120 mg lanreotide (Somatuline

269 Long-acting reversible contraception (LARC), specificall

270 el (LNG)-releasing intra-uterine systems for long-acting reversible contraception provides strong imp

271 Long-acting reversible contraceptive methods include int

272 intervention to increase patients' access to long-acting reversible contraceptives (LARCs) on pregnan

273 implants and intrauterine devices (IUDs) are long-acting reversible contraceptives (LARCs) that are k

274 there has been an emphasis on development of long-acting reversible contraceptives.

275 cohort study designed to promote the use of long-acting, reversible contraceptive (LARC) methods to

276 1042 to 672 (relative reduction, 35.5%) for long-acting, reversible contraceptives and from 6832 to

277 l, and vaginal) before and after exposure to long-acting rilpivirine for assessment of pharmacokineti

278 ltiple injections and help ascertain whether long-acting rilpivirine should advance to assessment of

279 Exposure to long-acting rilpivirine suppressed viral replication sig

280 tramuscular dose of either 1200 mg or 600 mg long-acting rilpivirine, beginning with the 1200 mg dose

281 armacokinetic and pharmacodynamic profile of long-acting rilpivirine.

282 re more common in the oral group than in the long-acting risperidone group (chi21 = 6.1; P = .01).

283 before randomization but was better for the long-acting risperidone group compared with the oral gro

284 bation and/or relapse rate was lower for the long-acting risperidone group compared with the oral gro

285 Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent th

286 The use of long-acting sedative agents may confound neurologic asse

287 y provides a means to extend the action of a long-acting, slow, effective release of antiretroviral t

288 (68)Ga-DOTATATE uptake before treatment with long-acting somatostatin analogs differs from that after

289 rials demonstrated antitumor activity of the long-acting somatostatin analogues octreotide long-actin

290 In addition to the use of long-acting somatostatin analogues, targeting the mammal

291 are modestly augmented by the addition of a long-acting ss-agonist.

292 To expedite the development of long acting, stable chemerin analogs as candidate therap

293 This may be a novel, long-acting strategy for the development of therapeutic

294 se two modalities can be combined to produce long-acting therapeutics with dual pharmacology and enha

295 Chlorthalidone is a potent, long-acting thiazide-like diuretic and should be used pr

296 Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs expo

297 Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged sys

298 ation of a tumor-homing TRAIL sensitizer and long-acting TRAILPEG.

299 trolled trial, we investigated the effect of long-acting vitamin D3 (400,000 IU) on sputum neutrophil

300 mmediate postretrieval bilateral blockade of long-acting voltage-dependent calcium channels (L-VDCCs)